Compare SOHU & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOHU | LYEL |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.1M | 320.1M |
| IPO Year | 2018 | 2021 |
| Metric | SOHU | LYEL |
|---|---|---|
| Price | $12.84 | $15.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $20.00 | ★ $30.60 |
| AVG Volume (30 Days) | 59.9K | ★ 248.1K |
| Earning Date | 05-18-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $1.61 | N/A |
| Revenue Next Year | $3.78 | $8,712.13 |
| P/E Ratio | $1.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.61 | $9.03 |
| 52 Week High | $17.30 | $45.00 |
| Indicator | SOHU | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 53.05 |
| Support Level | $11.61 | $11.59 |
| Resistance Level | $15.91 | $19.02 |
| Average True Range (ATR) | 0.49 | 1.48 |
| MACD | 0.16 | 0.50 |
| Stochastic Oscillator | 79.87 | 65.29 |
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.